Vivesto’s Paccal Vet Posts Positive Cat Cancer Topline, Offering Hope Where “Why Is My Cat Not Eating” Has Few Answers
Executive Summary. Swedish pharmaceutical company Vivesto AB announced positive topline results for Paccal Vet, its paclitaxel formulation studied in cats with cancer, in a press release published on 17 September 2026. The company said the data support continued clinical development. The result matters because more than 95 million cats live in the United States, roughly 6 million are diagnosed with cancer each year, and no drug is currently approved for the treatment of cancer in cats.
Key Facts
- Company
- Vivesto AB (Sweden)
- Product
- Paccal Vet (paclitaxel formulation for veterinary use)
- Event
- Positive topline results in feline study, supporting continued clinical development
- Date
- 2026-09-17, 10:08 CEST (regulated disclosure under the EU Market Abuse Regulation)
- Market context
- More than 95 million cats in the United States; approximately 6 million feline cancer diagnoses per year; no approved feline cancer drugs
- Source
- Vivesto AB press release
What Happened
Vivesto AB, a Swedish specialty pharmaceutical company, published positive topline results from its feline study of Paccal Vet on 17 September 2026 at 10:08 CEST. The release was submitted as regulated information under the EU Market Abuse Regulation. Vivesto said the results support continued clinical development of the product for cats. The company framed the unmet need in stark terms: there are an estimated 95 million or more cats in the United States alone, approximately 6 million of those are diagnosed with cancer each year, and there are currently no approved drugs for the treatment of cancer in cats.
Background
Paclitaxel is a established human oncology chemotherapy agent, but the formulation that works for people does not transfer directly to animals. Vivesto stated that current paclitaxel formulations are not tolerated by cats, which has kept the drug class out of feline medicine despite its effectiveness in human oncology. Paccal Vet is Vivesto’s veterinary program built on reformulation technology designed to make the molecule usable in companion animals. The positive topline readout is the evidence gate that determines whether the program advances to further clinical development.
Industry Context
Feline medicine has long trailed canine medicine in drug development, and cancer is the sharpest example: dogs have approved oncology therapeutics, cats have none. Most owners first notice something is wrong through behavior, searching reasons why is my cat not eating or why is my cat throwing up, because cats instinctively hide disease until it is advanced. By the time a diagnosis lands, owners face surgery, palliative care or nothing at all. Nutrition supports the journey, and senior cat food formulations are designed for aging cats, but diet cannot treat cancer. A tolerated chemotherapy option would give veterinarians an actual treatment tier between surgery and palliation for the species that owners most often diagnose late.
Market & Business Impact
Oncology is among the fastest-growing premium segments in companion animal veterinary care, driven by pet owners’ willingness to extend quality life years. If Paccal Vet advances, it would enter a US market of roughly 6 million new feline cancer diagnoses per year with zero approved drug competition. The commercial read-through extends to pet insurers, which would see a new claim category with defined protocols, and to veterinary oncology practices, which currently treat cats with off-label or supportive approaches only. Vivesto did not publish a development timeline in the release, so revenue timing cannot be verified.
Companies & Brands Involved
Vivesto AB is listed in Sweden and develops reformulated pharmaceuticals; Paccal Vet is its veterinary oncology candidate. Industry participants tracking animal-health suppliers and veterinary pharmaceutical companies can compare profiles in the GlobalPetIndex company directory.
Data & Evidence
Sourced figures from the 17 September 2026 release: more than 95 million cats in the United States; approximately 6 million US cats diagnosed with cancer each year; no approved drugs for cancer treatment in cats; current paclitaxel formulations are not tolerated by cats. The company did not disclose response rates, survival curves or study size in the topline announcement, so efficacy claims beyond “positive topline results” cannot be independently verified at this stage.
What This Means for the Pet Industry
A positive topline in a feline cancer program is a supply signal for the entire cat care economy: approved feline oncology would convert today’s palliative spending into structured treatment pathways, pulling insurers, specialty clinics and therapeutic nutrition into one protocol. Vivesto’s data also raises the bar for animal-health competitors that have deprioritized feline indications, because the first approved drug would own the category definition.
Key Takeaways
- Vivesto AB published positive topline results for Paccal Vet in a feline cancer study on 17 September 2026 and said the data support continued clinical development.
- The United States has more than 95 million cats and roughly 6 million feline cancer diagnoses per year, with no approved drug for feline cancer currently on the market.
- Current paclitaxel formulations are not tolerated by cats, which is the formulation barrier Paccal Vet is designed to overcome.
- An approved feline chemotherapy would create a treatment tier that today exists only for dogs, affecting insurers, oncology practices and therapeutic nutrition suppliers.
Frequently Asked Questions
What happened?
Vivesto AB announced positive topline results from its feline study of Paccal Vet on 17 September 2026, stating that the data support continued clinical development of the paclitaxel formulation for cats.
What is Paccal Vet?
Paccal Vet is Vivesto’s veterinary formulation of paclitaxel, a chemotherapy agent used in human oncology. Conventional paclitaxel is not tolerated by cats, so the program is built on a reformulation intended to make the molecule usable in feline patients.
Why is this significant for cats?
There are currently no approved drugs for the treatment of cancer in cats, despite roughly 6 million US feline cancer diagnoses each year, so any product that completes development would be first in class.
What signs usually prompt owners to see a vet?
Because cats hide illness, the first search is often why is my cat not eating, followed by why is my cat throwing up or sudden weight loss; these are late-stage warning signs, which is why veterinary oncologists emphasize regular check-ups for cats over ten years old.
When could Paccal Vet reach clinics?
Vivesto has not published a development timeline or regulatory submission date. The 17 September 2026 release states only that the topline results support continued clinical development, so clinic availability timing cannot be verified today.
